cGMP ‘biologics plant of the future’ starts operation in June
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, is to open a new cGMP custom biopharmaceutical manufacturing plant in Brisbane, Australia, in June.
The DSM facility has been built with the cooperation of the Queensland and Commonwealth Governments of Australia.
‘We are thrilled to announce the June opening our of new cGMP facility in Brisbane,’ said Karen King, President of DSM Biologics, the biopharmaceutical manufacturing business of DSM Pharmaceutical Products. ‘This operation combines DSM's 25 years of experience and high quality track record in mammalian cell culture manufacturing with a state-of-the-art commercial and development facility.’ She added that the plant would be an important addition to the Australian biotechnology industry and a key contributor to the entire Asia-Pacific region.
This operation combines DSM's 25 years of experience and high quality track record in mammalian cell culture manufacturing with a state-of-the-art commercial and development facility
Australia has a vibrant biotechnology industry, but previously had no custom mammalian-based biopharmaceutical manufacturing operation in the country. The Queensland Government formed BioPharmaceuticals Australia (BPA), which has partnered DSM to bring this new facility and operation to Brisbane.
David Hughes, CEO of BioPharmaceuticals Australia, said: ‘The opening of this facility satisfies a national capability gap. Our partnership gives Australia and the wider region access to DSM's extensive experience, expertise and ongoing commitment to developing improved bioprocessing technologies. DSM's operations are a good strategic fit with Australia's existing capabilities and we are already seeing flow-on benefits from local alliances.’
The DSM operation will provide cGMP mammalian cell-culture contract manufacturing services from process development through to commercial manufacturing. DSM Biologics operates with all standard technologies and also has a portfolio of proprietary technologies for the optimisation of biopharmaceutical manufacturing, reducing the cost and risk of mammalian cell culture. The facility has an annual output capability of 500kg, with room for further capacity expansion.